- Define and address unmet research needs in inflammatory skin conditions and enhance their investigation via collaborative, multicenter efforts.
- Research and discover best therapies, as well as allow assessment of biomarkers, genetic influences, and disease co-morbidities.
- Facilitate the study of new agents developed through translational medicine initiatives.
Background/Historical Perspective The PeDRA Inflammatory Skin Disease Collaborative (ISDC) was initiated on September 1, 2009, as the first multicenter effort for the study of pediatric inflammatory dermatoses. It brings together investigators with prior successful collaborations in clinical research and newer members developing careers in this area. The Collaborative has been productive via joint phone conferences held every 1-2 months and in-person meetings twice yearly. ISDC recognizes the broad set of disorders it covers and defined six areas for focused study at the first PeDRA Annual Conference in October 2013: psoriasis, atopic dermatitis, connective tissue and auto-inflammatory disorders, acne and hidradenitis, hair/nail/special site disorders, and therapeutics. Therapeutics was noted to be its own category as well as a part of all the others. The long-term objective of the Collaborative is to engage more dermatology centers to broaden the patient base and to collaborate with other clinicians and scientists working in the field.
Collaborative Research We welcome additional investigators and other studies of interest! Please contact the respective leads below.
Subgroups, Leads, and Contacts
– Amy Paller, MD; Kelly Cordoro, MD
– This investigator group is studying current practice patterns among those who care for children with psoriasis. This includes health screening and the use of systemic therapies, which will involve both retrospective review and development of a prospective observational study using standard protocols. Other areas of interest include the assessment of quality of life of caregivers of children with psoriasis.
– The AD subgroup launched the first clinical study of ISDC, focused on comparing the four main systemic agents for severe disease and their benefits, risks, and response. It is also studying multiple other aspects of the condition, including: the impact of co-morbidities and secondary complications (such as infection), factors impacting on treatment adherence and response, and differences in management across providers and countries.
-This subgroup is focused on acquired connective tissue diseases and other autoinflammatory disorders such as morphea and cutaneous lupus erythematosus. Collaborative prospective studies in development include a morphea registry and biobank, a morphea treatment survey, and a cutaneous lupus natural history study.
– A first focus is on pre-adolescent acne, including further characterization of the entity and determination of impact on quality of life. Additional areas of interest include the impact of early treatment on disease trajectory, as well as the effects on the acne microbiome.
-The subgroup is first studying alopecia areata, which several studies in preparation that examine treatment, as well as the potential effects of topical and systemic steroid use on growth parameters in children.
– currently integrated with the other 5 subgroups